[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"progression\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:progression":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,68,99,126,157,185,206,227,247],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100640360","construction-of-a-cohort-of-elderly-patients-with-atrial-fibrillation-in-rural-china-100640360",false,"NCT07611084","Construction of a Cohort of Elderly Patients With Atrial Fibrillation in Rural China","Inclusion Criteria:\n\n1. Permanent residents with local household registration in rural China.\n2. Aged 65-80 years.\n3. Electrocardiogram confirmation of AF or possession of a diagnostic certificate for AF issued by a specialist.\n4. Willing to participate in HF screening.\n5. Ability to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n1. Expected life expectancy of less than 3 months.\n2. Severe renal insufficiency (Ccr \\\u003C 30ml\u002Fmin) or ongoing dialysis treatment.\n3. Cardiac insufficiency secondary to correctable causes, including hyperthyroid heart disease, anemic heart disease, or uncorrected congenital heart disease.\n4. Indications for pacemaker implantation without having undergone implantation.\n5. Chronic obstructive pulmonary disease complicated by type II respiratory failure.\n6. Special populations, including patients with mental illnesses.","ALL","65 Years","80 Years",{"count":19,"type":20},2500,"ESTIMATED","OBSERVATIONAL","Atrial fibrillation (AF) is a common arrhythmia in aging populations and is strongly associated with an increased risk of heart failure (HF) and adverse cardiovascular outcomes. However, early detection of HF among patients with AF remain inadequate in rural settings. This study aims to screen for HF among older adults with AF in rural China and to conduct long-term follow-up in order to observe the disease progression in patients with AF.\n\nThis study will recruit at least 2,500 elderly individuals aged between 65 and 80 years, with confirmed diagnoses of AF, residing in rural areas. Participants will undergo HF screening using NT-proBNP testing and echocardiographic assessment. Additionally, data will be collected on electrocardiographic signals, seismocardiography, voice, and demographic characteristics. Following data collection, participants will be followed up every three months to monitor the incidence and progression of HF as well as the occurrence of adverse cardiovascular events.",[24,25,26,27],"Atrial Fibrillation (AF)","Heart Failure","Screening","Progression","RECRUITING","2026-05-22",{"date":31,"type":32},"2026-05-28","ACTUAL",{"date":34,"type":32},"2026-03-14",{"date":36,"type":20},"2029-12-31",{"name":38,"class":39},"Jiangsu Taizhou People's Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":40},"100437315","phase-2-trial-of-stereotactic-body-radiation-therapy-sbrt-for-oligoprogression-on-immune-checkpoint-inhibitors-ici-in-metastatic-renal-cell-carcinoma-100437315","NCT04974671","Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma","Phase II Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma","Inclusion Criteria:\n\nIn order to be eligible for participation in this trial, the subject must:\n\n1. Be willing and able to provide written informed consent\u002Fassent for the trial\n2. Be ≥ 18 years of age on day of signing informed consent.\n3. Have histologically confirmed renal cell carcinoma with metastatic disease detected on imaging. Biopsy of metastasis is preferred but not required\n4. The subject has a performance status of 0, 1, or 2 on the ECOG Performance Scale\n5. The life expectancy is \\> 6 months\n6. The most recent systemic therapy must be an ICI-containing regimen, delivered for at least 3 months prior to development of oligoprogressive lesions, with the last dose received within 3 months of trial enrollment.\n7. Oligoprogression - defined as documented progression in up to 5 individual lesions with no previous local therapy to those sites using one of the following criteria:\n\n   7.1 RECIST 1.1 7.1.1 At least a 20% increase in the sum of diameters of target lesions (long axis for non-nodal lesions, short axis for nodal lesions), using the previous imaging as a baseline 7.1.2 The sum of all diameters must demonstrate an absolute increase of at least 5 mm 7.1.3 The appearance of at least one new unequivocal lesion 7.2 PERCIST 7.2.1 SUVpeak, normalized to lean body mass (SUL) increase by at least 30% and increase by at least 0.8 SUL of the target lesion 7.2.2 Development of at least one new lesion 7.2.3 Increase in target lesion size by 30% 7.2.4 Unequivocal progression of nontarget lesions 7.3 Progressive enlargement of a known metastasis on 2 consecutive imaging studies at least 2 months apart with a minimum 5 mm increase in size 7.4 Development of a new soft tissue metastatic lesion at least 5 mm in size or any new bone metastasis\n8. There is no restriction on the total number of metastases\n9. Demonstrate adequate organ function as defined in Table 4, all screening labs should be performed within 28 days of protocol treatment\n\n   Table 4 Adequate Organ Function Laboratory Values\n\n   System Laboratory Value\n\n   Hematological\n\n   Absolute neutrophil count (ANC) ≥ 1,500 \u002FmcL Platelets ≥ 75,000 \u002F mcL Hemoglobin ≥ 9 g\u002FdL\n\n   Renal - IF SBRT will be delivered to a lesion in or abutting the kidney\n\n   Serum creatinine OR ≤1.5 X upper limit of normal (ULN) OR Measured or calculated\\* creatinine clearance (GFR can also be used in ≥30 mL\u002Fmin for subject with creatinine place of creatinine or CrCl) levels \\> 1.5 X institutional ULN\n\n   Hepatic - IF SBRT will be delivered to a lesion in or abutting the liver\n\n   Serum total bilirubin ≤ 1.5 X ULN Direct bilirubin Direct bilirubin ≤ ULN for subjects with total bilirubin levels \\> 1.5 ULN AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR\n   * 5 X ULN for subjects with liver metastases\n\n     * Creatinine clearance should be calculated per institutional standard\n10. Able to be treated with SBRT at a Yale radiation oncology facility\n11. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of SBRT. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n12. Female subjects of childbearing must use an effective form of birth control during this study. Acceptable and highly effective birth control methods include intra-uterine hormone releasing system as well as other methods of birth control including consistent use of an approved oral contraceptive (birth control pill), an implantable contraceptive, an injectable contraceptive, a double-barrier method, or true abstinence. Oral, implantable, or injectable contraceptives are only considered effective if used properly and started at least 30 days prior to the screening visit and continue for 120 days after last dose of study drug. (Reference Section 5.7)\n13. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy\n\nExclusion Criteria:\n\nThe subject must be excluded from participating in the trial if the subject\n\n1. Has had radiation therapy within 2 weeks of the first protocol treatment.\n2. Has brain-only oligoprogression. subjects with brain and systemic oligoprogression can still be considered, however treatment of brain metastases will be per standard of care prior to receiving study SBRT.\n3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks of the first protocol treatment. The use of lowdose steroids for management of chronic conditions is allowed (up to 12mg prednisone orally per day or the equivalent).\n4. Has had prior radiation therapy within 2 weeks of the first protocol treatment.\n5. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.\n6. Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma\u002Fatopy would be an example of an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Those with a history of hypothyroidism who are now stable on hormone replacement will not be excluded. Those with Sjorgen's syndrome will not be excluded from the study.\n7. Has a history of (non-infectious) pneumonitis that required steroids, current pneumonitis, or underlying lung disease that according to the treating physician makes the patient ineligible.\n8. Has an active infection requiring systemic therapy.\n9. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.\n10. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n11. Has received a live vaccine within 30 days prior to the first protocol treatment.\n12. Has serious medical comorbidities precluding radiotherapy. These include subjects with connective tissue diseases such as lupus or scleroderma, Crohn's disease in subjects where the GI tract will receive radiation\n13. Substantial overlap with a previously treated radiation volume. Prior radiotherapy is allowed as long as the composite plan meets dose constraints","18 Years",{"count":50,"type":20},30,"INTERVENTIONAL",[53],"PHASE2","This Phase II trial will evaluate progression-free survival after Stereotactic Body Radiation Therapy to oligoprogressive (1-5) lesions in metastatic renal cell carcinoma patients on any immune checkpoint inhibitor-containing regimen with last dose of systemic therapy within 3 months prior to trial enrollment.",[56,57,58,27],"Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Oligoprogressive","2025-12-03",{"date":61,"type":32},"2025-12-04",{"date":63,"type":32},"2023-12-22",{"date":65,"type":20},"2028-04-01",{"name":67,"class":39},"Yale University",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":15,"minAge":48,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":40},"100402865","liver-disease-and-other-systemic-diseases-100402865","NCT04525833","Liver Disease and Other Systemic Diseases","The Association of Liver Disease With Other Systemic Diseases, Focus on Diseases Progression, Treatments, and Clinical Outcomes: Analyses From the Hospital Database of Buddhist Tzu Chi Medical Foundation","Inclusion Criteria:\n\n* Individuals who visited the gastroenterology clinics of the Tzu Chi Hospitals, Buddhist Tzu Chi Medical Foundation\n\nExclusion Criteria:\n\n* Age younger than 18 or older than 99 years",true,"99 Years",{"count":78,"type":20},15000,"Examine the association of chronic liver diseases (including hepatitis B, hepatitis C, alcoholic liver disease, fatty liver, liver cirrhosis, and hepatocellular carcinoma) with other systemic diseases by retrospectively analyzing the data from the Hospital Database of Buddhist Tzu Chi Medical Foundation.",[81,82,27,83,84,85,86,87,88,89],"Liver Diseases","Humans","Carcinogenesis","Fatty Liver Disease","Hepatitis C","Hepatitis B","Hepatocellular Carcinoma","Liver Cirrhoses","Treatment Outcome","2025-09-16",{"date":92,"type":32},"2025-09-19",{"date":94,"type":32},"2020-01-01",{"date":96,"type":20},"2026-12-31",{"name":98,"class":39},"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":51,"phases":109,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100593613","phase-3-omitting-ctv-for-primary-tumor-in-ls-sclc-100593613","NCT07008716","Omitting CTV for Primary Tumor in LS-SCLC","Omission of Clinical Target Volume (CTV) for Primary Tumors in Limited-Stage Small Cell Lung Cancer: A Prospective Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Small cell lung cancer confirmed by histology or cytology; TNM stage IA-IIIC (AJCC 8th edition, 2017; limited-stage) without intrapulmonary metastasis;\n2. Aged 18-75 years, KPS score ≥ 80, ≤ 10% weight loss within the past 6 months;\n3. Have measurable lesions per RECIST 1.1 criteria;\n4. Have no disease progression after 2-4 cycles of etoposide\u002Fcarboplatin or etoposide\u002Fcisplatin;\n5. Lung function test: FEV1 ≥ 1 L (Optional);\n6. Complete blood count: neutrophil count ≥ 1.5 x 10\\^9\u002FL, hemoglobin ≥ 100 g\u002FL, platelet count ≥ 100 x 10\\^9\u002FL;\n7. Renal function: serum creatinine ≤ 1.5 x upper limit of normal (ULN);\n8. Liver function: AST and ALT ≤ 2.5 x ULN, bilirubin ≤ 1.5 x ULN;\n9. Fully understand the study, able to complete treatment and follow-up, and voluntarily sign the informed consent.\n\nExclusion Criteria:\n\n1. Other malignant tumors (prior or concurrent), except those that have been curatively treated with disease-free survival ≥ 5 years, such as non-melanoma skin cancer, cervical carcinoma in situ, or early-stage papillary thyroid cancer;\n2. Uncontrolled heart disease or myocardial infarction within the past 6 months;\n3. Patients with a history of mental illness;\n4. Pregnant and lactating patients;\n5. Poorly controlled diabetes and hypertension;\n6. Interstitial pneumonia or active pulmonary fibrosis;\n7. Active infection;\n8. Other conditions unsuitable for enrollment (per investigator judgment).","75 Years",{"count":108,"type":20},852,[110],"PHASE3","This randomized controlled non-inferior trial prospectively enrolled patients with limited-stage small cell lung cancer (LS-SCLC). Patients in the experimental group would receive radiotherapy with omission of the clinical target volume (CTV) for the primary tumor, while those in the control group would receive radiotherapy including CTV. The efficacy and toxicity of the two groups are compared to provide evidence for the radiotherapy of LS-SCLC. The target volume of LS-SCLC may be reduced by omitting CTV without increasing local recurrence but potentially reducing the dose to organs at risk and the side effects.",[113,114,115,27],"SCLC, Limited Stage","Radiation Exposure","Radiotherapy Side Effect","2025-05-29",{"date":118,"type":32},"2025-06-06",{"date":120,"type":20},"2025-06-03",{"date":122,"type":20},"2032-12-31",{"name":124,"class":39},"Sun Yat-sen University",2,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":75,"sex":134,"minAge":48,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":51,"phases":137,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":5},"100500082","the-norwegian-world-health-organisation-labour-care-guide-trial-norwel-100500082","NCT05791630","The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL)","The Norwegian World Health Organisation Labour Care Guide Trial","NORWEL","Inclusion Criteria:\n\n* Women in active labour\n* Labour and delivery at study sites\n\nExclusion Criteria:\n\n* None","FEMALE",{"count":136,"type":20},23650,[138],"NA","Appropriate and timely care during birth is critical to the survival and health of women and their babies. In 2020, the World Health Organization (WHO) presented the Labour Care Guide (LCG) as the new recommended tool for monitoring birth and assessing progression, replacing the WHO partograph. This evidence-based guide was designed to ensure improved quality and safety of care, and to avoid unnecessary interventions during birth. The LCG was developed to be used in all settings globally, but it has only been tested in health facilities in South America, Asia and Africa, while it has not been tested in high-income settings. Implementing a new guideline for monitoring birth is a comprehensive operation that will affect both the national economy, health systems, and individual patients; therefore, further research on the possible advantages is needed before national enrolment. Hence, the trial proposed in this application is crucial to form the required foundation of knowledge. The trial will be conducted in labour wards at ten hospitals, covering all health regions in Norway, and the established Norwegian Research Network for Clinical Studies in Obstetrics (NORBIRTH), with dedicated local principal investigators, will provide a robust research environment. This trial will test the effect of the LCG. Results from this trial will provide knowledge needed to determine a future implementation of the LCG in Norway.",[141,142,143,144,145,27,146,147],"Labor Dystocia","Labor Complication","Labor Onset and Length Abnormalities","Labor (Obstetrics)--Complications","Experience, Life","Cesarean Section Complications","Apgar; 4-7 at 1 Minute","2025-04-02",{"date":150,"type":32},"2025-04-04",{"date":152,"type":32},"2025-04-01",{"date":154,"type":20},"2030-12-31",{"name":156,"class":39},"Ostfold Hospital Trust",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":15,"minAge":165,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":51,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":183,"locationsCount":125},"100552384","phase-2-everolimus-5-mg-vs-10-mgdaily-for-patients-with-neuroendocrine-tumors-100552384","NCT06472388","Everolimus 5 mg vs 10 mg\u002FDaily for Patients With Neuroendocrine Tumors","Randomized Phase II Trial of Everolimus 5 mg vs 10 mg\u002FDaily for Patients With Advanced Neuroendocrine Tumors","EVENET","Inclusion Criteria:\n\n* Histological confirmation of well-differentiated Grade 1\u002FGrade 2 NET from gastrointestinal, pancreatic, pulmonary or unknown primary sites.\n* Metastatic or locally advanced and unresectable disease, measurable by images\n* Disease progression by RECIST 1.1 in the last 6 months assessed by local investigators\n* At least one previous line of systemic treatment (suspended for more than 3 weeks).\n* Eastern Cooperative Oncology Group (ECOG) 0-2 o Good organ function:\n\n  * Hemoglobin \\> 8 g\u002FdL\n  * Neutrophils ≥ 1,500\u002Fmm³\n  * Platelets \\> 90,000\u002Fmm³\n  * Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN \\[upper limit of normal\\] or ≤ 5 x ULN for patients with liver metastases\n  * Bilirubin ≤ 1.5 x ULN, creatinine \\\u003C 1.5 mg\u002FdL\n\nExclusion Criteria:\n\n* Aggressive disease requiring cytotoxic therapy\n* Severe\u002Funcontrolled comorbid conditions that deem participant unfit for everolimus therapy, as per investigators' judgement.\n* MiNEN","16 Years",{"count":167,"type":20},100,[53],"Everolimus is approved in many countries to treat patients with advanced\u002Fmetastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different types of NET. However, it is can cause severe adverse effects. Phase I trial demonstrated that a dose of 5mg\u002Fday\u002Fweek was sufficient to inhibit cell proliferation by blocking the mTOR pathway.\n\nThis is a randomized, open-label, phase II near-equivalence clinical trial of oral everolimus 5 mg vs 10 mg oral\u002Fdaily and continuously in patients with Grade 1 or Grade 2 metastatic NET, with tumor progression or intolerance to at least one line of treatment and with radiological disease progression within 6 months.",[171,27,172,173,174,175,176],"Neuroendocrine Tumors","Neuroendocrine Tumor Grade 1","Neuroendocrine Tumor Grade 2","Neuroendocrine Tumor of Pancreas","Neuroendocrine Tumor of the Lung","Neuroendocrine Tumor Carcinoid","2024-06-18",{"date":179,"type":32},"2024-06-25",{"date":181,"type":32},"2024-04-24",{"date":96,"type":20},{"name":184,"class":39},"AC Camargo Cancer Center",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":197,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":4},"100547549","tumor-cell-plasticity-and-aggressiveness-in-human-non-small-cell-lung-cancer-100547549","NCT06409416","Tumor Cell Plasticity and Aggressiveness in Human Non-small Cell Lung Cancer","Identification of Molecular Mechanisms Which Drive Tumor Cell Plasticity and Aggressiveness in Human Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* patients diagnosed with lung adenocarcinoma\n* treatment naive\n* undergoing primary surgery\n\nExclusion Criteria:\n\n* patients with a previous history of cancer\n* previously treated by chemio\u002Fimmuno\u002Fradio-therapy",{"count":193,"type":20},20,"Tumor cell plasticity (TCP) is a conubium of processes which lead to re-activation of developmental programs correlating with epithelial-to-mesenchymal transition, and ultimately leading to acquisition of stem cell properties and transdifferentiation potential. Little is known about the molecular mechanisms governing TCP in lung adenocarcinoma (LUAD), i.e. the most frequent lung cancer subtype. The investigators recently identified prognostic 7-miRNAs\u002F10-mRNAs signatures which accurately identified aggressive LUAD among patients with early-stage disease (Stage I). Furthermore, the investigators showed that such tumors show TCP features i.e. mesenchymal and stem-cell traits, high-metastatic potential. Here, the investigators aim to explore by RNAseq and by immunophenotyping at a single-cell level (scRNAseq\u002FAbSeq), the molecular features of aggressive LUAD to unveil the mechanisms triggering TCP. The investigators predict thier results will be relevant for the development of more effective therapeutic protocols for management of aggressive LUAD.",[196,27],"Lung Neoplasms","NOT_YET_RECRUITING","2024-06-17",{"date":177,"type":32},{"date":201,"type":20},"2024-07-01",{"date":203,"type":20},"2026-06-01",{"name":205,"class":39},"Casa Sollievo della Sofferenza IRCCS",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":15,"minAge":212,"maxAge":106,"enrollmentInfo":213,"targetDuration":4,"studyType":51,"phases":215,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":197,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":225,"locationsCount":4},"100453460","a-single-center-study-on-the-effect-of-systemicselective-lymph-node-dissection-on-the-prognosis-of-ground-glass-nodules-smaller-than-3cm-and-with-components-with-consolidationtumor-ratio-between-05-1-100453460","NCT05184829","A Single-center Study on the Effect of Systemic\u002FSelective Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With Components With Consolidation\u002FTumor Ratio Between 0.5-1","Inclusion Criteria:\n\nPatients enrolled in the study must meet all of the following conditions:\n\n* 1.Aged between 25 and 75 years;\n* 2\\. GGO is diagnosed by thin-section lung CT (thickness \\\u003C1.5mm) within one month before surgery;\n* 3\\. The maximum diameter of the GGO is smaller than 3cm;\n* 4\\. The solid component in GGO between 50%-100%;\n* 5\\. Preoperative examination showed that the patient could tolerate lobectomy;\n* 6\\. The patient is able to understand and comply with the study and has provided written informed consent.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria are not eligible for this trial:\n\n* 1\\. Patients with a history of lung surgery;\n* 2\\. Postoperative pathology showed non-primary lung cancer;\n* 3\\. The scope of surgical resection is larger than one lung lobe;\n* 4\\. Patients with a history of other tumors;\n* 5\\. Patients with severe complications (coronary heart disease, valvular heart disease, end-stage renal disease, severe liver cirrhosis);\n* 6\\. Unable to cooperate with the researchers because of dementia or cognitive decline\n* 7\\. Other situations that are not in conformity with the standards and requirements of this trial.","25 Years",{"count":214,"type":20},500,[138],"A single-center study on the effect of systemic\u002Fselective lymph node dissection on the prognosis of ground glass nodules smaller than 3cm and with components with consolidation\u002Ftumor ratio between 0.5-1",[27,218],"Postoperative Recovery","2021-12-28",{"date":221,"type":32},"2022-01-11",{"date":223,"type":20},"2022-01-01",{"date":36,"type":20},{"name":226,"class":39},"Shanghai Zhongshan Hospital",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":51,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":40},"100431972","phase-2-a-prospective-two-center-single-arm-phase-ii-clinical-study-to-evaluate-safety-and-effectiveness-of-ablation-therapy-in-the-treatment-of-lung-cancer-presenting-as-ground-glass-nodules-100431972","NCT04905056","A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules","Inclusion Criteria:\n\n1. Aged between 18 and 85 years;\n2. GGO is diagnosed by lung CT and failure to subside after 3 months (the patient having been re-examined by thin-section CT);\n3. The maximum diameter of the GGO is bigger than 8mm and smaller than 3cm;\n4. For single GGO: obvious progress was observed in pure GGO or the solid component of mixed ground glass nodules was more than or equal to 2 mm\n5. The patients were unable to tolerate the operation for various reasons or multiple grinding glass nodules, operation can not be completely removed; or patients had received surgery in ipsilateral chest\n6. The patient is able to understand and comply with the study and has provided written informed consent\n\nExclusion Criteria:\n\n1. Patients who participated in any drug and \u002F or medical device clinical trials within one month before the trial\n2. had severe disease conditions\n3. allergy to narcotic drugs\n4. had other autoimmune disease\n5. dementia or cognitive impairment can't cooperate with researchers\n6. any local treatment other than ablation was received within 4 weeks before the study","85 Years",{"count":235,"type":20},120,[53],"A prospective, two-center, single arm phase II clinical study to evaluate safety and effectiveness of ablation therapy in the treatment of lung cancer presenting as ground-glass nodules",[27],"2021-05-23",{"date":241,"type":32},"2021-05-27",{"date":243,"type":32},"2021-01-01",{"date":245,"type":20},"2028-12-31",{"name":226,"class":39},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":106,"enrollmentInfo":254,"targetDuration":4,"studyType":51,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":265,"locationsCount":40},"100407107","a-multiple-center-study-on-the-effect-of-different-ways-of-lymph-node-dissection-on-the-prognosis-of-ground-glass-nodules-smaller-than-3cm-and-with-more-than-50-solid-components-100407107","NCT04581122","A Multiple-center Study on the Effect of Different Ways of Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With More Than 50% Solid Components","Zhongshan Hospital","Inclusion Criteria:\n\n1. Aged between 18 and 75 years;\n2. GGO is diagnosed by lung CT and failure to subside after 3 months (the patient having been re-examined by thin-section CT);\n3. The maximum diameter of the GGO is smaller than 3cm;\n4. The maximum diameter of the solid component in the GGO is more than 50%;\n5. The patient is able to undergo the lobectomy\n6. The patient is able to understand and comply with the study and has provided written informed consent.\n\nExclusion Criteria:\n\n\\-\n\nPatients meeting any of the following criteria are not eligible for this trial:\n\n1. Patients with a history of using immunosuppressive or hormonal drugs;\n2. Patients receiving radiotherapy or chemotherapy;\n3. Patients who fail to comply with our follow-up strategy;\n4. Other situations that are not in conformity with the standards and requirements of this trial.",{"count":255,"type":20},1500,[138],"A multiple-center study on the effect of different ways of lymph node dissection on the prognosis of less than 3cm ground glass nodules with more than solid components",[27],"2020-10-08",{"date":261,"type":32},"2020-10-09",{"date":263,"type":32},"2020-09-01",{"date":245,"type":20},{"name":226,"class":39}]